Background
==========

Biological Therapies
--------------------

Biologic therapies, or biologicals, are those produced or extracted from a biological source. Based upon the specific agent, biologicals have a myriad of activities and have been used to modulate immunity, increase blood cell production, inhibit tumor growth, and other effects \[[@B1]\]. Over the last 5 years, more than 20% of the compounds approved by United States regulatory authorities were biologics \[[@B2]\]. Despite this explosion in the availability of biologicals, surprisingly limited data exists regarding adverse events associated with their use.

Because these compounds are derived from biologic sources, they have the potential for significant immune activation. Although extensively reported in clinical trials, adverse events are rarely compiled in the medical literature. Giezen and coauthors examined adverse event reporting post-approval for biologicals and suggested that there was a need for increasing awareness to certain risks associated with the therapeutic use of biologicals \[[@B2]\].

Cetuximab (Erbitux^®^)
----------------------

One such biologic therapy used in the treatment of malignancy is cetuximab (Erbitux^®^, ImClone, Branchburg, NJ). Cetuximab is a chimeric monoclonal antibody with inhibitor effects on the epidermal growth factor receptor (EGFR). Cetuximab has been extensively studied and approved \[[@B3]\] for the treatment of metastatic colorectal cancer (MCRC) and squamous cell head/neck cancers (SCCHN), and growing data supports its use in the treatment of other malignancies including non-small cell lung cancer (NSCLC). Cetuximab has been evaluated in the setting of combination therapy or as a single agent in conventional therapy failures. Moreover, cetuximab has been studied for the treatment of various other malignancies including breast cancer and ovarian cancer, hepatocellular cancer, pancreatic cancer, and others.

Through binding to the extracellular domain of EGFR, cetuximab interrupts the signaling cascade resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production \[[@B3]\]. EGFR, a member of the ErbB-1 family of receptors, is closely related structurally to other tyrosine kinase receptors including HER2/c-neu (ErbB-2), Her 3 (ErbB-3), and Her 4 (ErbB-4)\[[@B4]\]. Over expression or increased activity of EGFR as seen in some mutations can result malignancy \[[@B4]\].

Cetuximab efficacy has been studied as a single agent as well as in combination with other chemotherapeutic modalities. A randomized controlled clinical trial with 329 patients was conducted using cetuximab plus irinotecan or cetuximab alone in treatment of EGFR-expressing MCRC \[[@B3]\]. Cetuximab was shown to lengthen the time to disease progression by 4.2 months in the monotherapy arm and 5.7 months in combination arm. In patients with EGFR-positive NSCLC a phase II study by Rosell showed that combination cisplatin/vinorelbine plus cetuximab resulted in an overall response rate of 32%, compared to 20% with cisplatin/vinorelbine alone \[[@B5]\]. The continuing research of cetuximab is helping to determine which populations of patient will benefit most from Anti-EGFR therapy. Currently most evidence points towards the use of cetuximab in combination with other chemotherapeutic regimens as the best option for treatment in EGFR positive tumors.

Epidermal growth factor receptors are ubiquitous, thus potential for exuberant reactions including adverse events is high. Moreover, due to the diverse tissues expressing EGRF, adverse reactions manifest in many ways. Although dermatologic reactions represent the vast majority of adverse events, occurring in between 30-90% of patients depending on the severity and study examined \[[@B6],[@B7]\], many other side effects occur with cetuximab therapy. Other adverse events increased above control groups included gastrointestinal complaints (19-59%) and headache (19%) \[[@B3]\]. Cextuximab infusion reactions took place in between 15 and 20% of subjects \[[@B3]\].

There have only been rare reports of pulmonary side effects with cetuximab. Interstitial lung disease was reported in 4 of 1,570 (0.25%) patients with advanced colorectal cancer \[[@B3]\]. There have also been reports of interstitial pneumonitis with non-cardiogenic pulmonary edema \[[@B8]\]. The use of cetuximab in combination regimens potentially clouds side effect profiles.

Pulmonary complications in the setting of chemotherapy lead to increased morbidity and severe reactions are associated with mortality. Cetuximab, like many other cancer therapies, has been demonstrated to cause a wide range of respiratory effects from mild dyspnea to a fatality due adverse pulmonary events. The purpose of this investigation is to compile a comprehensive list of pulmonary adverse events in the setting of therapy with cetuximab published in the literature in order to better characterize the true incidence of these reactions. A better understanding of the prevalence may help the clinician respond appropriately to specific symptom changes during the therapeutic window with a hope of improving patient care.

Methods
=======

We performed a MEDLINE™ search of the English language literature using the search terms: \"cetuximab\" or \"Erbitux\" with limits to include only human studies to develop a complete index of trials or reports. Inclusion criteria were clinical trials, meta-analyses, or randomized controlled trials that included the search terms and cited adverse events. The reference lists from each of these manuscripts were scanned to isolate articles not obtained in the MEDLINE^®^search to complete our database. Studies were excluded if they did not list adverse events.

Data extracted from each report included number of patients, controls, type of cancer, coincident chemotherapy administration, and information regarding pulmonary complications. Pulmonary complications included the incidence of symptoms related to the respiratory system including dyspnea, cough, wheezing, pneumonia, hypoxemia, respiratory insufficiency/failure, pulmonary embolus, pleural effusion, and non-specific respiratory disorders. Incidences of these pulmonary complications were obtained from each study\'s control group if available and compared between the patients that received cetuximab and those who did not. Infusion reactions were treated as a separate complication to cetuximab and were not included in this analysis, although in many individuals, symptoms of shortness of breath and chest tightness may be encompassed by this type of reaction \[[@B9]\].

Data Analysis and Statistics
----------------------------

Data is presented as the number of patients and percentage receiving the study medication as well as means (± SD) where appropriate. Comparisons between groups were made using Chi-Square or students t-test where appropriate, and statistical significance was set as p \< 0.05.

Results
=======

Using our search criteria defined above, a total of 245 articles were obtained for review. From this complete group, 192 articles were excluded for not meeting inclusion criteria. Reasons for exclusion were: non-pulmonary focus (dermatologic side effects), duplicate patient populations, case reports not relevant to pulmonary side effects, focus on pharmacokinetics, omission of side effects, or non-cetuximab trials. A total of 53 studies (Table [1](#T1){ref-type="table"}) met inclusion and were included in the analysis \[[@B5],[@B8],[@B10]-[@B60]\].

###### 

Studies included in the analysis including first author, year of publication, type of trial and combined therapy, and pulmonary adverse reactions.

  **Number**   **Ref:**   **Author**         **Year**   **Study Type**   **Cancer Type**      **Combined Agents**                              **Pulmonary Reactions**
  ------------ ---------- ------------------ ---------- ---------------- -------------------- ------------------------------------------------ --------------------------------------------------
  1            51         Vermorken          2008       Phase II         SCCHN                platinum                                         dyspnea, Pneumonia
  2            29         Koo                2007       Phase II         Colorectal           FOLFIRI, irinotecan                              dyspnea
  3            8          Leard              2007       case             SCCHN                                                                 DAD
  4            16         Burtness           2005       Phase III        SCCHN                cisplatin                                        dyspnea, hypoxia
  5            15         Bourhis            2006       Phase I/II       SCCHN                cisplatin, carboplatin/5-fluorouracil            respiratory symptoms
  6            12         Baselga            2005       Phase II         SCCHN                platinum                                         respiratory disorder
  7            50         Vermorken          2007       review           SCCHN                cisplatinum, carboplatin                         dyspnea, infusion rxn
  8            20         Cunningham         2004       Prospective      Colorectal           irinotecan                                       dyspnea
  9            53         Xiong              2004       Phase II         Pancreatic           gemcitabine                                      Pneumonia, Sepsis, PE, Pulm Insufficeincy
  10           19         Chan               2005       Phase II         Nasopharyngeal       carboplatin                                      Pleural Effusion, Dyspnea, Pneumonia
  11           40         Robert             2005       Phase I/II       NSCLC                gemcitibine, carboplatin                         Pulmonary Embolism
  12           23         Hanna              2006       Phase II         NSCLC                                                                 Dyspnea
  13           54         Zhu                2007       Phase II         HCC                                                                   Cough
  14           31         Machiels           2007       Phase I/II       Colorectal           capecitabine, ExBR                               Pulmonary Embolism, Pulm Infetion
  15           13         Bonner             2006       RCT              SCCHN                ExBR                                             cough, increased sputum
  16           32         Martin-Martorell   2008       Phase II         Colorectal           irinotecan                                       none
  17           28         Konner             2008       Phase II         Ovarian              carboplatin, paclitaxel                          Dyspnea
  18           56         Hughes             2008       Phase I/II       NSCLC                platinum, ExBR 64 Gy                             dyspnea, pneumonitis, pulm embolism, pneumonia
  19           11         Asnacios           2008       Phase II         HCC                  oxaliplatin, gemcitabine                         none
  20           18         Cascinu            2008       Phase II         Pancreatic           cisplatin, gemcitabine                           none
  21           35         Paule              2007       Phase II         Cholangiocarcinoma   oxaliplatin, gemcitabine                         none
  22           47         Tabernero          2007       Phase II         Colorectal           oxaliplatin, 5-fluorouracil                      Dyspnea
  23           27         Jonker             2007       rescue           Colorectal           prev-oxal, irinotecan, flouropyrimidine          dyspnea
  24           42         Safran             2008       phase II         Espohageal           carboplatin, paclitaxel, ExBR                    Pneumonia
  25           26         Ibrahim            2007       phase II         Colorectal           oxaliplatin, irinotecan                          none
  26           38         Pinto              2007       phase II         Gastric/GE           irinotecan, 5-fluorouracil                       none
  27           46         Souglakos          2007       phase II         Colorectal           oxaliplatin, capecitabine                        none
  28           30         Lenz               2006       phase II         Colorectal           prev-oxaloplatin, irinotecan, flouropyrimidine   none
  29           25         Hofheinz           2006       phase I          Colorectal           capecitabine, irinotecan, ExBR                   none
  30           24         Herbst             2005       phase II         SCCHN                cisplatin                                        none
  31           43         Saltz              2004       phase II         Colorectal           previous irinotecan                              none
  32           52         Vincenzi           2006       phase II         Colorectal           irinotecan                                       none
  33           37         Pfister            2006       phase II         SCCHN                cisplatin, ExBR                                  pneumonia
  34           39         Robert             2001       phase I          SCCHN                ExBR                                             none
  35           48         Thienelt           2005       Phase I/II       NSCLC                carboplatin, paclitaxel                          pulmonary embolism
  36           34         Neyns              2008       Phase II         Colorectal           oxaloplatin or irinotecan                        Interstitial pneumonitis
  37           10         Arnold             2008       Phase Ib/II      Colorectal           oxaliplatin, 5-fluorouracil                      None
  38           45         Sobrero            2008       Phase III        Colorectal           irinotecan                                       None
  39           44         Secord             2008       Phase II         Ovarian              carboplatin                                      Pulmonary rxn
  40           14         Borner             2008       Phase II         Colorectal           oxaliplatin, capecitabine                        none
  41           21         Gamucci            2008       Phase II         Colorectal           irinotecan                                       none
  42           49         Tol                2008       Phase III        Colorectal           capecitabine, Oxaliplatin + Bevacizumab          Pulmonary embolism, Respiratory Insuffiency
  43           17         Butts              2007       Phase II         NSCLC                gemcitabine, Cisplatin, Carboplatin              dyspnea, Cough, Pneumonia
  44           36         Pessino            2008       Phase II         Colorectal           none                                             none
  45           5          Rosell             2008       Phase II         NSCLC                cisplatin, vinorelbine                           resp symptoms
  46           41         Rodel              2008       Phase I/II       Colorectal           capecitabine, ExBR, Oxaliplatin                  none
  47           33         Modi               2006       Phase I          Breast               paclitaxel                                       none
  48           22         Gebbia             2006       retrospect rev   Colorectal           irinotecan                                       none
  49           58         Pirker             2009       Phase III        NSCLC                cisplatin, vinorelbine                           dyspnea, respiratory failure, pulmonary embolism
  50           57         Belani             2008       Phase II         NSCLC                carboplatin, docetaxel                           none
  51           55         Gridelli           2009       Phase II         NSCLC                gemcitibine                                      pulmonary symptoms
  52           59         Shin               2001       Phase I          SSCHN                Cisplatin                                        Shortness of Breath
  53           60         Baselga            2000       Phase I          SSCHN/NSCLC          Cisplatin                                        Dyspnea

(Abbreviations: SCCHN - squamous cell cancer of the head and neck, NSCLC - non-small cell lung cancer, ExBR - external beam radiation)

The majority of clinical trials focused on the treatment of colorectal cancers with head/neck, lung, and hepatobiliary or pancreatic making up the next largest groups (Table [1](#T1){ref-type="table"}). Similarly, most of the studies examined were completed as Phase I or II trials with the focus on refractory and metastatic disease (Table [2](#T2){ref-type="table"}).

###### 

Number and type of trials broken into groups according to cancer type.

  Trial Type                      Cancer Type           
  -------------------- ---- ----- ------------- --- --- ----
  Phase I/II           20   9\*   10\*          5   3   47
  Phase III            2    1     1             0   0   4
  Case Series/Review   1    0     1             0   1   3
  TOTAL                23   10    12            5   4   53
                                                        
  First-Line           5    2     0             0   2   9
  Refractory Disease   18   8\*   12\*          5   2   44

(NSCLCa - nonsmall cell lung cancer, HB-Panc - hepatobiliary or pancreatic, Breast-Ov-Skin - Breast or Ovarian or Cutaneous). \* One study contained patients with either Head-Neck or Non-small cell lung cancer and is displayed in both groups.

A total of 7,411 patients were included in the 53 studies reviewed including 4,436 (59.8%) patients who received cetuximab either alone or in conjunction with other chemotherapeutic medications or radiation therapy. 2,596 (41.4%) patients were in the control groups from these investigations who received the same chemotherapy or radiation therapy without cetuximab (Table [3](#T3){ref-type="table"}).

###### 

Number of patients included by trial type.

  Cancer Type                Studies Included   Total Patients   Number of Cetuximab   Cetuximab with Pulmonary Reaction   Number of Controls   Controls with Pulmonary Reaction
  -------------------------- ------------------ ---------------- --------------------- ----------------------------------- -------------------- ----------------------------------
                             n                  n                n                     n                                   n                    n
  Colorectal                 23                 3731             2227                  76 (3.4)                            1367                 35 (2.6)
  Head-Neck                  10                 1749             1004                  173 (17.2)                          516                  104 (20.2)
  Lung                       10                 1664             980                   189 (19.6) †                        671                  82 (12.2)
  Hepatobiliary/Pancreatic   5                  209              167                   9 (5.4)                             42                   0 (0.0)
  Breast/Ovarian             3                  78               78                    10 (12.8)                           0                    0 (0.0)
  Cutaneous                  1                  2                2                     2 (100)                             0                    0 (0.0)
  TOTAL:                     52                 7433             4458                  459 (10.3) †                        2596                 221 (8.5)

Patients were grouped into those who received cetuximab, either alone or in combination with other therapeutics, and controls (those who did not receive cetuximab). † p \< 0.05 compared to control group. \* One study contained patients with either Head-Neck or Non-small cell lung cancer and is displayed in both groups.

Pulmonary Reactions
-------------------

A total of 459 patients (10.3%) in the cetuximab group had adverse pulmonary reactions compared to 221 (8.5%) who received standard, non-cetuximab therapy (p \< 0.02). Studies focusing on colorectal cancer, lung cancer, and head-neck cancer had sufficient numbers in both the cetuximab and control groups to compare pulmonary complications; however, hepatobiliary, pancreatic, breast, ovarian, and cutaneous cancer studies lacked adequate numbers of control patients to compare these complications.

Colorectal cancer studies demonstrate a low rate of pulmonary complications overall with 3.41% incidence in the cetuximab group versus 2.56% in the control patients (p = NS). The most common side effect was dyspnea in these studies making up more than 90% of the adverse reactions.

Pulmonary adverse events were much more common, as would be expected in NSCLC trials with an incidence of 18.7% in the cetuximab group versus 12.2% in the control arms (p \< 0.001). Similarly, dyspnea made up the majority of pulmonary adverse events (13.2% vs 9.2%, p \< 0.02) with other significant differences occurring in the incidence of pneumonitis (1.1% versus 0.0%, p \< 0.001) being worse in the cetuximab groups.

For head-neck cancer studies, the overall rates of pulmonary complications were similar between the cetuximab and control groups (17.9% versus 20.1%, p = NS), but favored the cetuximab group. Dyspnea was more common in the cetuximab group (8.7%) than the control group (5%, p \< 0.02) in Head and Neck Cancer Trials. Conversely, there were fewer patients with increased sputum production (3.0% versus 6.6%, p \< 0.01) and cough (4.5% versus 7.8%, p \< 0.01) in the control group compared to the cetuximab group. From all studies, the difference in other pulmonary adverse events appears to be similar (Table [4](#T4){ref-type="table"}).

###### 

Combined pulmonary adverse events cited in clinical trials.

                     Colorectal Cancer Cetuximab   Control    Non-Small Cell Lung Cancer Cetuximab   Control     Head-Neck Cancer Cetuximab   Control
  ------------------ ----------------------------- ---------- -------------------------------------- ----------- ---------------------------- ------------
  Dyspnea/RI         70 (3.1)                      35 (2.6)   131 (13.4) †                           62 (9.2)    87 (8.7) †                   26 (5.0)
  PE                 3 (0.1)                       0 (0.0)    32 (3.3)                               16 (2.4)    0 (0.0)                      0 (0.0)
  Pneumonia          2 (0.1)                       0 (0.0)    4 (0.4)                                1 (1.2)     13 (1.4)                     4 (0.8)
  ILD                0 (0.0)                       0 (0.0)    0 (0.0)                                0 (0.0)     0 (0.0)                      0 (0.0)
  Cough              0 (0.0)                       0 (0.0)    8 (3.4)                                3 (3.6)     42 (4.5) †                   40 (7.8)
  Pneumonitis        1 (0.0)                       0 (0.0)    17 (1.7) †                             0 (0.0)     0 (0.0)                      0 (0.0)
  Pleural Effusion   0 (0.0)                       0 (0.0)    0 (0.0)                                0 (0.0)     3 (0.3)                      0 (0.0)
  Increased Sputum   0 (0.0)                       0 (0.0)    0 (0.0)                                0 (0.0)     28 (3.0) †                   34 (6.6)
  TOTAL:             76 (3.4)                      35 (2.6)   192 (19.6) †                           82 (12.2)   173 (17.9)                   104 (20.2)

Patients were grouped into those who received cetuximab, either alone or in combination with other therapeutics, and controls (those who did not receive cetuximab). † p \< 0.05 compared to control group.

Discussion
==========

Overall, cetuximab seems to increase the incidence of adverse pulmonary reactions compared to controls, although the absolute difference between groups is low (\<2%). The severity of the pulmonary complications was not well described in most of the included studies, but did not increase mortality rates. To the contrary, if survival benefits were not demonstrated, almost universally, there was an increase in progression free survival or stability of malignancy in these trials. To this point, the difference between statistical significance and clinical significance should also be examined in relation to the pulmonary reactions. For all clinical trials except NSCLC, the differences in pulmonary adverse events between those treated with and without cetuximab are small. Dyspnea and cough, though increased in the cetuximab groups, did not appear to limit the therapeutic course.

The observation of increased pulmonary adverse events in patients with NSCLC when compared to controls was striking. Again, most of the adverse reactions in these patients were dyspnea or respiratory insufficiency, and were not noted to be treatment limiting. Although the mechanism for increased symptoms in patients with NSCLC is not well defined, it is not surprising that those with a site of action in the lung would suffer from exuberant local effects. Pneumonitis was seen in most patients (71%) treated with cetuximab in combination with radiation therapy for NSCLC, although there was no control group in this study for comparison \[[@B56]\]. These patients had advanced disease and were treated with a radiation dose of 64Gy to the lungs, which is well above the threshold for pneumonitis with radiation alone\[[@B61]\] As expected, treatment of head/neck cancers in these trials had high overall rates of pulmonary adverse events, although there were no significant differences between those who received cetuximab and those who did not.

Severe adverse reactions were not common in clinical trials using cetuximab. Interstitial lung disease, cited as a rare complication in the medication\'s package insert, was not described in the clinical trials included in this review with the exception of a case report of two post-lung transplantation patients treated with cetuximab for cutaneous malignancy. Obviously, there are likely confounding factors which may have predisposed this select population to the development of diffuse alveolar damage. For those described in the cetuximab package insert, interstitial lung disease was present before the institution of cetuximab therapy for malignancy. Arguably, the increase in pulmonary symptoms in these patients may have been more a manifestation of ILD progression than as an effect of the therapeutic. However, the presence of antecedent parenchymal lung disease may abrogate the utility of cetuximab in select patients. Pulmonary embolism, also considered a severe reaction, occurred in small numbers of patients in the groups analyzed herein.

An association between the presence of malignancy in the lung, regardless of primary origin, and pulmonary adverse events could not be determined from this investigation. Of the 43 non-lung cancer studies included in our series only 9 reported the location of metastatic disease. When combined with studies of lung cancer, 17% of this cohort reported direct pulmonary involvement of cancer. In those defining the sites of metastatic foci, the lungs were involved in 46.0 ± 10% of patients. Primary or metastatic involvement of the lung with any cancer could account for patients experiencing pulmonary adverse events when treated with Cetuximab. Unfortunately, a more clear relationship is limited by the presentation of the data in the original studies.

Our investigation suffers from several limitations which should be pointed out. First, it is a compilation of clinical trials, most of which are early phase, with limited numbers including control populations available for comparison of pulmonary adverse events. Most of the studies examined only cited positive adverse events, omitting negative responses to pulmonary symptom changes. This may lead to an over-estimation of the absolute incidence of pulmonary-specific complications. Conversely, transfusion reactions and sepsis which often include symptoms such as dyspnea or respiratory insufficiency were not included in the present analysis due to lack of a clear definition. There were significant differences in the duration of Cetuximab therapy before pulmonary complications were reported in the clinical trials, ranging from 1 week into therapy to more than several months. This also limits the generalizability of the summation data. Finally, although there appears to be an increase in the incidence of pulmonary adverse events with cetuximab therapy, there is no clearly defined causal relationship that can be proven as mechanistic understandings are lacking. Despite these limitations, we believe that this investigation adds to the sparse literature describing the pulmonary adverse events related to cetuximab therapy.

Conclusion
==========

Cetuximab (Erbitux^®^ImClone, Branchburg, NJ) therapy, in combination or as monotherapy, is efficacious in the treatment of colorectal, head/neck, lung and possibly other cancers. Although there is an overall increase in the incidence of pulmonary adverse events with this treatment, there seems to be sparse evidence suggesting treatment limitations related to these complications. Particular attention should be given to cetuximab recipients with underlying parenchymal lung disease and those with NSCLC, in particular in conjunction with radiation therapy, as these groups may have more severe pulmonary reactions.

Abbreviations
=============

ILD: Interstitial lung disease; NSCLC: Non-small cell lung cancer; SCCHN: Squamous cell cancer/head and neck.
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